|Bid||112.00 x 1200|
|Ask||119.50 x 800|
|Day's Range||116.19 - 120.07|
|52 Week Range||102.10 - 140.77|
|Beta (3Y Monthly)||1.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 6, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||163.29|
Alexion Pharmaceuticals (ALXN) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in the third quarter. Also, the company???s revenues beat estimates.
In November 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Alexion Pharmaceuticals stock is 1.83 with a target price of $163.29, implying an upside potential of 28.4% over Alexion Pharmaceuticals’ closing price of $127.18 on November 10, 2018.
In October 2018, Alexion Pharmaceuticals (ALXN) entered a collaboration with Dicerna Pharmaceuticals that provides Alexion exclusive worldwide licenses and development and commercial rights to two molecules for complement-mediated diseases along with an exclusive option for other molecules for two additional targets within the complement pathway. Under the collaboration, Alexion will make an upfront payment of $37.0 million and could be required to pay up to ~$625.0 million in milestone payments and royalties on product sales.
Alexion Pharmaceuticals’ (ALXN) interest expense remained relatively flat at $24.6 million in the third quarter of 2018 as compared with $25.0 million in the year-ago period. Alexion Pharmaceuticals’ net income jumped from $78.0 million in the third quarter of 2017 to $330.9 million in the latest quarter, which translated into net earnings per share of $1.47 in the third quarter of 2018. Alexion’s recent major acquisitions include Wilson Therapeutics in May 2018 and Syntimmune in September 2018.
For fiscal 2018 and 2019, Alexion Pharmaceuticals’ gross margins are expected at 91.08% and 91.22%, respectively, as compared with gross margins of 91.95% for fiscal 2017. In comparison, fiscal 2018 gross margins for peers Abbott Laboratories (ABT), Amgen (AMGN), and Johnson & Johnson (JNJ) are expected at 59.29%, 85.73%, and 70.43%, respectively. Alexion Pharmaceuticals incurred selling, general, and administrative expenses of $258.7 million in the third quarter of 2018 as compared with $270.6 million in the third quarter of 2017.
Alexion Pharmaceuticals (ALXN), a global biopharmaceutical company, is a leader in complement inhibition and is focused on the therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. Alexion has brought to market the only approved complement inhibitor for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. Further, the company has two enzyme replacement therapies for hypophosphatasia and lysosomal acid lipase deficiency.
Alexion Pharmaceuticals’ (ALXN) key products on the market include Soliris, Strensiq, and Kanuma. Total Soliris sales increased from $755.4 million in the third quarter of 2017 to $888.0 million in the latest quarter. Its US sales increased from $307.6 million in the third quarter of 2017 to $404.5 million in the latest quarter. Its Europe sales increased from $248.4 million in the third quarter of 2017 to $262.1 million in the latest quarter.
The large-cap biopharma experienced its worst month of 2018. Then it raised full-year 2018 financial guidance.
Alexion Pharmaceuticals today announced that management will present at Credit Suisse’s 27th Annual Healthcare Conference in Scottsdale, AZ on Tuesday, November 13, 2018 at 10:00 a.m., ET.
Alexion Pharmaceuticals, Inc. (ALXN) today announced that the previously announced acquisition of Syntimmune has been successfully completed. The acquisition adds to the company’s growing pipeline with the addition of clinical-stage SYNT001, a humanized monoclonal antibody that inhibits the interaction of neonatal Fc receptor (FcRn) with Immunoglobulin G (IgG) and IgG immune complexes with the potential to treat a number of rare IgG-mediated diseases.
NEW YORK, Nov. 02, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / November 2, 2018 / U.S. markets rallied on Thursday, with the S&P 500 Index logging its first 3-day win streak in six weeks, as trade concerns between the U.S. and China continued ...
Alexion Pharmaceuticals, Inc. (ALXN) today announced that nine abstracts from its complement research and development program have been accepted for presentation at the American Society of Hematology (ASH) Annual Meeting in San Diego, December 1 to 4, 2018. Key data will include both new analyses and previously announced results from the two Phase 3 studies of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH), in addition to further data on Soliris® (eculizumab) for the treatment of PNH and atypical hemolytic uremic syndrome (aHUS).
Impressive third-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.
Alexion Pharmaceuticals (ALXN) released its third-quarter results on October 24. Boosted by the strong performance of Soliris and Strensiq, the company’s total revenues increased 20% from $859.1 million in the third quarter of 2017 to $1.03 billion in the third quarter. Alexion’s cost of sales decreased from $157.0 million in the third quarter of 2017 to $90.6 million in the third quarter.
Alexion posted an "impressive" 54% operating margin in the third quarter, leading to a big beat on adjusted earnings, but shares slid Wednesday as revenue missed some estimates.
Newly Massachusetts-based biotech Alexion Pharmaceuticals became the latest company to enter the gene silencing drug field, signing a deal with Dicerna Pharmaceuticals worth upwards of $637 million.